https://rijournals.com/scientific-and-experimental-sciences/

RESEARCH INVENTION JOURNAL OF SCIENTIFIC AND EXPERIMENTAL SCIENCES 5(2):12-16, 2025

©RIJSES Publications

ONLINE ISSN: 1115-618X

PRINT ISSN: 1597-2917

https://doi.org/10.59298/RIJSES/2025/521216

The Efficacy and Safety of Monoclonal Antibodies for the Prevention of Plasmodium Falciparum Malaria in High-Risk Pediatric Populations

Kansiime Agnes

Department of Clinical Medicine and Dentistry Kampala International University Uganda
agnes.kansiime.2974@studwc.kiu.ac.ug

ABSTRACT

Malaria caused by *Plasmodium falciparum* remains a leading cause of morbidity and mortality among children under five in sub-Saharan Africa, despite existing control measures such as insecticide-treated bed nets and antimalarial chemoprophylaxis. Monoclonal antibodies (mAbs) have emerged as a promising intervention for malaria prevention, offering immediate and long-lasting protection by targeting specific parasite antigens. This review synthesized evidence from preclinical studies, clinical trials, and real-world data to evaluate the efficacy and safety of mAbs in high-risk pediatric populations. Key findings highlight the potential of mAbs, such as CIS43LS and L9LS, to significantly reduce malaria infection and clinical episodes, with efficacy influenced by factors like antigen specificity, dosing, and epidemiological context. Safety profiles appear favorable, with most adverse events being mild to moderate, though long-term data and evaluations in vulnerable subpopulations are needed. Challenges such as high production costs, potential resistance, and integration into existing malaria control strategies must be addressed to ensure widespread accessibility and impact. This review underscored the transformative potential of mAbs in malaria prevention while calling for continued research, collaboration, and investment to optimize their use in protecting the most vulnerable children. By synthesizing current evidence, this article aimed to inform policymakers, healthcare providers, and researchers on the feasibility of integrating mAbs into malaria control programs to reduce the global burden of pediatric malaria.

Keywords: Monoclonal Antibodies, Plasmodium falciparum Malaria, Pediatric Populations, Malaria Prevention, Efficacy and Safety.

INTRODUCTION

Malaria remains one of the most significant global health challenges, particularly in sub-Saharan Africa, where *Plasmodium falciparum*, the most virulent malaria parasite, is endemic [1–3]. Pediatric populations in these regions bear the brunt of the disease, with children under five years of age accounting for most of the malaria-related morbidity and mortality. The World Health Organization (WHO) estimates that nearly 80% of malaria deaths in Africa occur in this vulnerable age group. Despite considerable advancements in malaria control strategies, including insecticide-treated bed nets, indoor residual spraying, and antimalarial chemoprophylaxis, the burden of malaria in high-risk pediatric populations remains unacceptably high. This has necessitated the exploration of novel interventions, among which monoclonal antibodies (mAbs) have emerged as a promising tool for malaria prevention. Monoclonal antibodies are laboratory-engineered molecules designed to mimic the immune system's ability to fight off pathogens [4, 5]. In the context of malaria, mAbs target specific antigens on the *P. falciparum* parasite, thereby preventing its invasion of red blood cells or facilitating its clearance by the immune system [6]. The potential of mAbs lies in their specificity, long half-life, and ability to provide immediate protection, making them particularly suitable for high-risk populations, including infants and young children. Recent clinical trials have demonstrated the

feasibility of using mAbs for malaria prevention, with some candidates showing high efficacy in reducing parasitemia and clinical malaria episodes. However, the translation of these findings into real-world settings requires a thorough evaluation of both efficacy and safety, especially in pediatric populations who may have unique immunological and physiological considerations. This review aims to critically assess the current evidence on the efficacy and safety of monoclonal antibodies for the prevention of *P. falciparum* malaria in high-risk pediatric populations. By synthesizing findings from preclinical studies, clinical trials, and real-world data, this article seeks to provide a comprehensive understanding of the potential role of mAbs in malaria prevention, identify knowledge gaps, and highlight areas for future research. The goal is to inform policymakers, healthcare providers, and researchers on the feasibility of integrating mAbs into existing malaria control strategies to achieve sustained reductions in malaria-related morbidity and mortality in children.

The Burden of Plasmodium Falciparum Malaria in Pediatric Populations

The disproportionate impact of *P. falciparum* malaria on pediatric populations, particularly in sub-Saharan Africa, is well-documented [7]. Children under five years of age are highly susceptible to severe malaria due to their lack of acquired immunity, which typically develops after repeated exposures to the parasite [8]. Severe malaria in this age group often manifests as cerebral malaria, severe anemia, or multi-organ failure, leading to high mortality rates. Even in non-fatal cases, malaria can have long-term consequences, including cognitive impairment, stunted growth, and increased susceptibility to other infections. These outcomes not only affect individual children but also place a significant economic burden on families and healthcare systems. Current malaria prevention strategies, while effective, have limitations that hinder their ability to fully protect high-risk pediatric populations. Insecticide-treated bed nets and indoor residual spraying are highly dependent on consistent usage and coverage, which can be challenging in resource-limited settings [9, 10]. Antimalarial chemoprophylaxis, such as intermittent preventive treatment in infants (IPTi), has shown promise but is limited by issues of drug resistance, adherence, and the need for repeated administration. These challenges underscore the need for innovative approaches that can provide robust and sustained protection against malaria in children.

Monoclonal Antibodies: Mechanism of Action and Rationale for Malaria Prevention

Monoclonal antibodies are designed to target specific antigens on the *P. falciparum* parasite, thereby disrupting its life cycle and preventing infection. One of the most promising targets for mAbs is the circumsporozoite protein (CSP), which is expressed on the surface of sporozoites, the infective form of the parasite transmitted by mosquitoes [11, 12]. By binding to CSP, mAbs can neutralize sporozoites before they invade hepatocytes, the first step in the parasite's life cycle. Other potential targets include merozoite surface proteins, which are involved in the invasion of red blood cells, and antigens expressed on infected erythrocytes, which play a role in immune evasion.

The rationale for using mAbs for malaria prevention is based on their ability to provide immediate and long-lasting protection. Unlike vaccines, which require time to induce an immune response, mAbs can confer protection immediately after administration. This is particularly advantageous for high-risk pediatric populations, who may not have the time to develop immunity through natural exposure or vaccination. Additionally, mAbs can be engineered to have an extended half-life, potentially providing protection for several months with a single dose. This feature makes mAbs an attractive option for seasonal malaria prevention or for use in areas with high transmission rates.

Efficacy of Monoclonal Antibodies in Pediatric Populations

Several clinical trials have evaluated the efficacy of monoclonal antibodies for malaria prevention in pediatric populations. One of the most notable candidates is CIS43LS, a mAb targeting the CSP of *P. falciparum [13]*. In a phase 1 trial conducted in Mali, a single intravenous dose of CIS43LS was shown to provide up to 100% protection against malaria infection for up to 36 weeks. These findings were subsequently confirmed in a phase 2 trial, where CIS43LS demonstrated high efficacy in preventing clinical malaria episodes in children aged 6-10 years. Similar results have been reported for other mAbs targeting CSP, including L9LS, which has shown promise in early-phase trials.

The efficacy of mAbs in preventing malaria is influenced by several factors, including the specificity and affinity of the antibody for its target antigen, the dose and route of administration, and the epidemiological context in which the mAb is deployed [14, 15]. For example, mAbs may be more effective in areas with seasonal malaria transmission, where a single dose can provide protection throughout the transmission season. In contrast, in areas with year-round transmission, the duration of protection provided by mAbs may be insufficient, necessitating repeated administration or combination with other interventions.

Safety of Monoclonal Antibodies in Pediatric Populations

The safety of monoclonal antibodies is a critical consideration, particularly in pediatric populations, who may have unique immunological and physiological responses to biologic therapies [16]. Overall, the safety profile of mAbs for malaria prevention appears to be favorable, with most adverse events being mild to moderate in severity. Common

side effects include injection site reactions, fever, and headache, which are generally self-limiting and resolve without intervention. However, there are concerns about the potential for immune-mediated adverse events, such as hypersensitivity reactions or the development of anti-drug antibodies, which could reduce the efficacy of the mAb or lead to adverse outcomes. Long-term safety data on mAbs for malaria prevention are limited, as most clinical trials have followed participants for less than a year. This is particularly relevant for pediatric populations, who may require repeated administrations of mAbs over several years. There is also a need to evaluate the safety of mAbs in specific subpopulations, such as infants, malnourished children, and those with comorbid conditions, who may be at increased risk of adverse events. Addressing these safety concerns will be essential for the successful implementation of mAbs in malaria-endemic regions [16, 17, 18, 19].

Challenges and Future Directions

Despite the promising results from clinical trials, several challenges must be addressed before monoclonal antibodies can be widely adopted for malaria prevention in pediatric populations. One of the primary challenges is the cost of production and delivery, which may limit the accessibility of mAbs in resource-limited settings [17]. Efforts to reduce costs, such as the development of more efficient production methods or the use of alternative delivery systems, will be critical for scaling up mAb-based interventions. Another challenge is the potential for the emergence of resistance to mAbs, particularly if they target a single antigen. To mitigate this risk, future research should focus on the development of mAbs that target multiple antigens or are used in combination with other interventions, such as vaccines or antimalarial drugs. Additionally, there is a need for more robust clinical trials to evaluate the efficacy and safety of mAbs in diverse epidemiological settings and across different age groups, including infants and young children [19, 20, 21, 22, 23].

Finally, the integration of mAbs into existing malaria control strategies will require careful planning and coordination. This includes the development of guidelines for the use of mAbs, training of healthcare providers, and community engagement to ensure acceptance and adherence. Policymakers will also need to consider the cost-effectiveness of mAbs relative to other malaria prevention strategies and prioritize their use in populations with the greatest need.

CONCLUSION

Monoclonal antibodies represent a promising new tool for the prevention of *Plasmodium falciparum* malaria in high-risk pediatric populations. Clinical trials have demonstrated their high efficacy in reducing malaria infection and clinical episodes, with a favorable safety profile. However, several challenges remain, including the need for long-term safety data, cost reduction, and strategies to prevent resistance. Addressing these challenges will require continued investment in research and development, as well as collaboration between researchers, policymakers, and healthcare providers. The potential impact of mAbs on malaria control in pediatric populations is significant. By providing immediate and long-lasting protection, mAbs could complement existing interventions and help to bridge the gap in malaria prevention for the most vulnerable children. As the field of monoclonal antibody therapy continues to advance, it is essential to prioritize the needs of high-risk pediatric populations and ensure that these innovative interventions are accessible to those who need them most. With sustained efforts, mAbs have the potential to play a transformative role in the global fight against malaria, bringing us closer to the goal of a malaria-free world.

REFERENCES

1. Alum, E.U., Tufail, T., Agu, P.C., Akinloye, D.I., Obaroh, I.O.: Malaria pervasiveness in Sub-Saharan Africa: Overcoming the scuffle. Medicine. 103, e40241 (2024). https://doi.org/10.1097/MD.0000000000040241
2. Alum, E.U., Ugwu, O.P.-C., Egba, S.I., Uti, D.E., Alum, B.N.: Climate Variability and Malaria Transmission: Unraveling the Complex Relationship. INOSR Scientific Research. 11, 16–22 (2024). https://doi.org/10.59298/INOSRSR/2024/1.1.21622
3. Milner, D.A., Vareta, J., Valim, C., Montgomery, J., Daniels, R.F., Volkman, S.K., Neafsey, D.E., Park, D.J., Schaffner, S.F., Mahesh, N.C., Barnes, K.G., Rosen, D.M., Lukens, A.K., Van Tyne, D., Wiegand, R.C., Sabeti, P.C., Seydel, K.B., Glover, S.J., Kamiza, S., Molyneux, M.E., Taylor, T.E., Wirth, D.F.: Human cerebral malaria and Plasmodium falciparum genotypes in Malawi. Malar J. 11, 35 (2012). https://doi.org/10.1186/1475-2875-11-35
4. Mekala, J.R., Nalluri, H.P., Reddy, P.N., Sainath, S.B., Sampath, S.K., Sai, S.K., Dhiman, R., Chamarthy, S., Komaragiri, R.R., Manyam, R.R., Dirisala, V.R.: Emerging trends and therapeutic applications of monoclonal antibodies. Gene. 925, 148607 (2024). https://doi.org/10.1016/J.GENE.2024.148607

5. Strzelec, M., Detka, J., Mieszczak, P., Sobocińska, M.K., Majka, M.: Immunomodulation—a general review of the current state-of-the-art and new therapeutic strategies for targeting the immune system. Front Immunol. 14, 1127704 (2023). https://doi.org/10.3389/FIMMU.2023.1127704/PDF
6. Antwi-Baffour, S., Mensah, B.T., Annison, L.: Overview of the host immune response to P. falciparum malaria. Journal of Parasitic Diseases 2025. 1–17 (2025). https://doi.org/10.1007/S12639-025-01802-6
7. Nasuuna, E., Kigozi, J., Muwanguzi, P.A., Babirye, J., Kiwala, L., Muganzi, A., Sewankambo, N., Nakanjako, D.: Challenges faced by caregivers of virally non-suppressed children on the intensive adherence counselling program in Uganda: A qualitative study. BMC Health Serv Res. 19, 1–10 (2019). https://doi.org/10.1186/S12913-019-3963-Y/FIGURES/2
8. Anjorin, S., Okolie, E., Yaya, S.: Malaria profile and socioeconomic predictors among under-five children: an analysis of 11 sub-Saharan African countries. Malar J. 22, 1–11 (2023). https://doi.org/10.1186/S12936-023-04484-8/TABLES/4
9. Erisa, K., Raphael, I., Okechukwu Paul-Chima, U., Esther Ugo, A.: Exploration of Medicinal Plants Used in the Management of Malaria in Uganda.
10. Al-Worafi, Y.M.: Malaria Management in Developing Countries. Handbook of Medical and Health Sciences in Developing Countries. 1–40 (2024). https://doi.org/10.1007/978-3-030-74786-2_60-1
11. Livingstone, M.C., Bitzer, A.A., Giri, A., Luo, K., Sankhala, R.S., Choe, M., Zou, X., Dennison, S.M., Li, Y., Washington, W., Ngauy, V., Tomaras, G.D., Joyce, M.G., Batchelor, A.H., Dutta, S.: In vitro and in vivo inhibition of malaria parasite infection by monoclonal antibodies against Plasmodium falciparum circumsporozoite protein (CSP). Scientific Reports 2021 11:1. 11, 1–15 (2021). https://doi.org/10.1038/s41598-021-84622-x
12. Fernández-Arias, C., Mashoof, S., Huang, J., Tsuji, M.: Circumsporozoite protein as a potential target for antimalarials. Expert Rev Anti Infect Ther. 13, 923–926 (2015). https://doi.org/10.1586/14787210.2015.1058709
13. Wang, L.T., Idris, A.H., Kisalu, N.K., Crompton, P.D., Seder, R.A.: Monoclonal antibodies to the circumsporozoite proteins as an emerging tool for malaria prevention. Nature Immunology 2024 25:9. 25, 1530–1545 (2024). https://doi.org/10.1038/s41590-024-01938-2
14. Aleshnick, M., Florez-Cuadros, M., Martinson, T., Wilder, B.K.: Monoclonal antibodies for malaria prevention. Molecular Therapy. 30, 1810–1821 (2022). https://doi.org/10.1016/J.YMTHE.2022.04.001
15. Miura, K., Flores-Garcia, Y., Long, C.A., Zavala, F.: Vaccines and monoclonal antibodies: new tools for malaria control. Clin Microbiol Rev. 37, (2024). https://doi.org/10.1128/CMR.00071-23/ASSET/842E9625-47B3-4C58-9C22-2A7E5A10DA6F/ASSETS/IMAGES/LARGE/CMR.00071-23.F004.JPG
16. Edlund, H., Melin, J., Parra-Guillen, Z.P., Kloft, C.: Pharmacokinetics and Pharmacokinetic–Pharmacodynamic Relationships of Monoclonal Antibodies in Children. Clin Pharmacokinet. 54, 35–80 (2015). https://doi.org/10.1007/S40262-014-0208-4/METRICS
17. Guttieres, D.G.: Closing gaps in global access to biologic medicines: building tools to evaluate innovations in biomanufacturing. (2018).
18. Obeagu, E. I., Alum, E. U. and Ugwu, O. P. C. Hepcidin's Antimalarial Arsenal: Safeguarding the Host. NEWPORT INTERNATIONAL JOURNAL OF PUBLIC HEALTH AND PHARMACY. 2023; 4(2):1-8. https://doi.org/10.59298/NIJPP/2023/10.1.1100
19. Okechukwu PC Ugwu, Okwesili FC Nwodo, Parker E Joshua, Christian E Odo, Abubakar Bawa, EC Ossai, CC Adonu Anti-malaria and hematological analyses of ethanol leaf extract of Moringa oleifera on malaria infected mice *International Journal of Pharmacy and Biological Science* 2013. *3(1) 360-371.*
20. Okechukwu PC Ugwu, OFC Nwodo, PE Joshua, CE Odo, EC Ossai, B Aburbakar.Ameliorative effects of ethanol leaf extract of *Moringa oleifera* on the liver and kidney markers of malaria infected mice. 2013.*2(2) 43-52.*
21. Okechukwu PC Ugwu, Okwesili FC Nwodo, Parker E Joshua, Christian E Odo, Emmanuel C Ossai The effect of ethanol leaf extract of *Moringa oleifera* on the lipid profile of malaria infected mice *Journal of applied science* 2013. *4(1) 1324-1332.*
22. Enechi OC, CC Okpe, GN Ibe, KO Omeje, PC Ugwu Okechukwu. Effect of Buchholzia coriacea methanol extract on haematological indices and liver function parameters in Plasmodium berghei-infected mice Global Veterinaria 2016. 16(1) 57-66.
23. Okechukwu Paul-Chima Ugwu Anti-Malaria Effect of Ethanol Extract of Moringa Oleifera (Agbaji) Leaves on Malaria Induced Mice. *University of Nigeria Nsukka*, 2011. *39.*

CITE AS: Kansiime Agnes (2025). The Efficacy and Safety of Monoclonal Antibodies for the Prevention of Plasmodium Falciparum Malaria in High-Risk Pediatric Populations. RESEARCH INVENTION JOURNAL OF SCIENTIFIC AND EXPERIMENTAL SCIENCES 5(2):12-16. https://doi.org/10.59298/RIJSES/2025/521216